Viewing Study NCT04501120

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 4:29 AM
Ignite Modification Date: 2026-01-25 @ 12:22 AM
Study NCT ID: NCT04501120
Status: RECRUITING
Last Update Posted: 2025-09-26
First Post: 2020-08-03
Is Gene Therapy: True
Has Adverse Events: False
Brief Title: Study of Lisaftoclax (APG-2575) Single Agent and Combination With Therapy in Patients Relapsed/Refractory AML
Sponsor: Ascentage Pharma Group Inc.
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Relapsed/Refractory Acute Myeloid Leukaemia View
None Myeloid Malignancy View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Acute Myeloid Leukaemia (AML) View
None Bcl-2 Inhibitor View
None Myeloid Malignancy View
None Lisaftoclax (APG-2575) View